The delta - 9 - THC synthesis or dronabinol, active substance of the medicinal product Marinol, registered in the USA with indications in cases of loss of appetite and weight in patients with AIDS, is not classified by the INCB between narcotic substances (yellow list) but between the psychotropic substances (green list); nabilone, active substance of the medicinal product Cesamet, registered in the USA with indications as an antiemetic in course of chemotherapy, is under control in Italy and in some other countries. Any preparations with a basis of dronabinol require a prescription not repeatable. Up to now, for the realization of the preparations with vegetable products based on cannabis were imported into Italy only the products marketed by the Office of Medicinal Cannabis (Dutch agency for cannabis) of the Dutch Ministry of Health, Welfare and Sport, in accordance with the procedure for the scheduled import from DM 11/2/97. In 2016, our country has launched a national production of cannabis for medical use at the Military Pharmaceutical Chemical Works of Florence (SCFM), thanks to the collaboration between the Ministry of Health and the Ministry of Defense, in such a way as to ensure that the access to such therapies to appropriate costs and safely. This is the Cannabis product FM-2 (containing THC 5% - 8% and CBD 7.5% - 12%), before the active substance based on cannabis produced in accordance with the European directives in the field of medicinal products (EU - GMP) on production process deposited and controlled in a pharmaceutical workshop authorized by the AIFA and the distribution of which is authorized by the State body for cannabis at the Ministry of Health. The prescription of cannabis for medical use in Italy concerns (DM 9/11/2015) use in chronic pain and that associated with multiple sclerosis and spinal cord injury; in the nausea and vomiting caused by cancer chemotherapy, radiotherapy, therapy for HIV; as stimulating appetite in cachexia, Anorexia, loss of appetite in cancer patients or suffering from AIDS and anorexia nervosa; the hypotensive effect in glaucoma; the reduction of involuntary movements of the body and facial tissues in of Gilles de la Tourette Syndrome. The requirements are carried out when the conventional therapies or standard are ineffective. Information is available for doctors and pharmacists and instructions for the preparation of the decoction. In order to deepen see: Law 08 April 1998 , n. 94. Conversion to law, with amendments, of the decree-law of 17 February 1998, n. 23 laying down urgent provisions in the field of clinical trials in the field of oncology and other measures in the area of health. Order of 18 July 2006. Importation of medicines based on delta-9-tetrahydrocannabinol and trans-delta-9-tetrahydrocannabinol The Ministerial Decree of 18 April 2007. Updating and completion of the tables containing the indication of narcotic and psychotropic substances and related compositions medicinal products referred to in the decree of the President of the Republic 9 October 1990, n. 309, and subsequent modifications and integrations, bearing the consolidated text of the laws on discipline of narcotic drugs and psychotropic substances and of prevention, care and rehabilitation of the related member of drug addiction The Ministerial Decree of 23 January 2013. Update the tables containing the indication of narcotic and psychotropic substances, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent modifications and integrations. Insertion in Table II, Section B, of medicinal products of plant origin based on Cannabis (substances and preparations plants including extracts and tinctures) The plants of the genus cannabis are known for millennia and used in the past especially for the characteristics of resistance of the fiber for the production of fabrics and ropes. The genus cannabis spp. Comprises Species, varieties and subspecies indistinguishable between them as morphologically similar. All plants of the genus cannabis contain in various concentrations between 400 and 750 different substances, of these about 40 are cannabinoids including the tetrahydrocannabinol or THC and cannabidiol or CBD, active substances present in the medicinal products authorised in Italy and abroad (see American Herbal Pharmacopoeia). The inflorescences of cannabis are tabellate as drugs and their use in the pharmaceutical field is subject to prior authorization as provided for in the United Nations Conventions of 1961 and 1971 and the national legislation on drugs (Decree of the President of the Republic 309/90 and subsequent amendments or single text of drugs). The inflorescences of cannabis plants with high THC content (> 0.2%) must be transformed into active substances of vegetable origin in accordance with the European directives in the field of medicinal products. In addition to the prior authorization to the cultivation, the law provides that the sale can be made only to pharmaceutical workshops authorised for processing into medicinal products and active substances. The delta - 9 - THC synthesis or dronabinol, active substance of the medicinal product Marinol, registered in the USA with indications in cases of loss of appetite and weight in patients with AIDS, is not classified by the INCB between narcotic substances (yellow list) but between the psychotropic substances (green list); nabilone, active substance of the medicinal product Cesamet, registered in the USA with indications as an antiemetic in course of chemotherapy, is under control in Italy and in some other countries. Any preparations with a basis of dronabinol require a prescription not repeatable. Up to now, for the realization of the preparations with vegetable products based on cannabis were imported into Italy only the products marketed by the Office of Medicinal Cannabis (Dutch agency for cannabis) of the Dutch Ministry of Health, Welfare and Sport, in accordance with the procedure for the scheduled import from DM 11/2/97. In 2016, our country has launched a national production of cannabis for medical use at the Military Pharmaceutical Chemical Works of Florence (SCFM), thanks to the collaboration between the Ministry of Health and the Ministry of Defense, in such a way as to ensure that the access to such therapies to appropriate costs and safely. This is the Cannabis product FM-2 (containing THC 5% - 8% and CBD 7.5% - 12%), before the active substance based on cannabis produced in accordance with the European directives in the field of medicinal products (EU - GMP) on production process deposited and controlled in a pharmaceutical workshop authorized by the AIFA and the distribution of which is authorized by the State body for cannabis at the Ministry of Health. The prescription of cannabis for medical use in Italy concerns (DM 9/11/2015) use in chronic pain and that associated with multiple sclerosis and spinal cord injury; in the nausea and vomiting caused by cancer chemotherapy, radiotherapy, therapy for HIV; as stimulating appetite in cachexia, Anorexia, loss of appetite in cancer patients or suffering from AIDS and anorexia nervosa; the hypotensive effect in glaucoma; the reduction of involuntary movements of the body and facial tissues in of Gilles de la Tourette Syndrome. The requirements are carried out when the conventional therapies or standard are ineffective. Information is available for doctors and pharmacists and instructions for the preparation of the decoction. In order to deepen see: Law 08 April 1998 , n. 94. Conversion to law, with amendments, of the decree-law of 17 February 1998, n. 23 laying down urgent provisions in the field of clinical trials in the field of oncology and other measures in the area of health. Order of 18 July 2006. Importation of medicines based on delta-9-tetrahydrocannabinol and trans-delta-9-tetrahydrocannabinol The Ministerial Decree of 18 April 2007. Updating and completion of the tables containing the indication of narcotic and psychotropic substances and related compositions medicinal products referred to in the decree of the President of the Republic 9 October 1990, n. 309, and subsequent modifications and integrations, bearing the consolidated text of the laws on discipline of narcotic drugs and psychotropic substances and of prevention, care and rehabilitation of the related member of drug addiction The Ministerial Decree of 23 January 2013. Update the tables containing the indication of narcotic and psychotropic substances, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent modifications and integrations. Insertion in Table II, Section B, of medicinal products of plant origin based on Cannabis (substances and preparations plants including extracts and tinctures) The plants of the genus cannabis are known for millennia and used in the past especially for the characteristics of resistance of the fiber for the production of fabrics and ropes. The genus cannabis spp. Comprises Species, varieties and subspecies indistinguishable between them as morphologically similar. All plants of the genus cannabis contain in various concentrations between 400 and 750 different substances, of these about 40 are cannabinoids including the tetrahydrocannabinol or THC and cannabidiol or CBD, active substances present in the medicinal products authorised in Italy and abroad (see American Herbal Pharmacopoeia). The inflorescences of cannabis are tabellate as drugs and their use in the pharmaceutical field is subject to prior authorization as provided for in the United Nations Conventions of 1961 and 1971 and the national legislation on drugs (Decree of the President of the Republic 309/90 and subsequent amendments or single text of drugs). The inflorescences of cannabis plants with high THC content (> 0.2%) must be transformed into active substances of vegetable origin in accordance with the European directives in the field of medicinal products. In addition to the prior authorization to the cultivation, the law provides that the sale can be made only to pharmaceutical workshops authorised for processing into medicinal products and active substances. The delta - 9 - THC synthesis or dronabinol, active substance of the medicinal product Marinol, registered in the USA with indications in cases of loss of appetite and weight in patients with AIDS, is not classified by the INCB between narcotic substances (yellow list) but between the psychotropic substances (green list); nabilone, active substance of the medicinal product Cesamet, registered in the USA with indications as an antiemetic in course of chemotherapy, is under control in Italy and in some other countries. Any preparations with a basis of dronabinol require a prescription not repeatable. Up to now, for the realization of the preparations with vegetable products based on cannabis were imported into Italy only the products marketed by the Office of Medicinal Cannabis (Dutch agency for cannabis) of the Dutch Ministry of Health, Welfare and Sport, in accordance with the procedure for the scheduled import from DM 11/2/97. In 2016, our country has launched a national production of cannabis for medical use at the Military Pharmaceutical Chemical Works of Florence (SCFM), thanks to the collaboration between the Ministry of Health and the Ministry of Defense, in such a way as to ensure that the access to such therapies to appropriate costs and safely. This is the Cannabis product FM-2 (containing THC 5% - 8% and CBD 7.5% - 12%), before the active substance based on cannabis produced in accordance with the European directives in the field of medicinal products (EU - GMP) on production process deposited and controlled in a pharmaceutical workshop authorized by the AIFA and the distribution of which is authorized by the State body for cannabis at the Ministry of Health. The prescription of cannabis for medical use in Italy concerns (DM 9/11/2015) use in chronic pain and that associated with multiple sclerosis and spinal cord injury; in the nausea and vomiting caused by cancer chemotherapy, radiotherapy, therapy for HIV; as stimulating appetite in cachexia, Anorexia, loss of appetite in cancer patients or suffering from AIDS and anorexia nervosa; the hypotensive effect in glaucoma; the reduction of involuntary movements of the body and facial tissues in of Gilles de la Tourette Syndrome. The requirements are carried out when the conventional therapies or standard are ineffective. Information is available for doctors and pharmacists and instructions for the preparation of the decoction. In order to deepen see: Law 08 April 1998 , n. 94. Conversion to law, with amendments, of the decree-law of 17 February 1998, n. 23 laying down urgent provisions in the field of clinical trials in the field of oncology and other measures in the area of health. Order of 18 July 2006. Importation of medicines based on delta-9-tetrahydrocannabinol and trans-delta-9-tetrahydrocannabinol The Ministerial Decree of 18 April 2007. Updating and completion of the tables containing the indication of narcotic and psychotropic substances and related compositions medicinal products referred to in the decree of the President of the Republic 9 October 1990, n. 309, and subsequent modifications and integrations, bearing the consolidated text of the laws on discipline of narcotic drugs and psychotropic substances and of prevention, care and rehabilitation of the related member of drug addiction The Ministerial Decree of 23 January 2013. Update the tables containing the indication of narcotic and psychotropic substances, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent modifications and integrations. Insertion in Table II, Section B, of medicinal products of plant origin based on Cannabis (substances and preparations plants including extracts and tinctures) The plants of the genus cannabis are known for millennia and used in the past especially for the characteristics of resistance of the fiber for the production of fabrics and ropes. The genus cannabis spp. Comprises Species, varieties and subspecies indistinguishable between them as morphologically similar. All plants of the genus cannabis contain in various concentrations between 400 and 750 different substances, of these about 40 are cannabinoids including the tetrahydrocannabinol or THC and cannabidiol or CBD, active substances present in the medicinal products authorised in Italy and abroad (see American Herbal Pharmacopoeia). The inflorescences of cannabis are tabellate as drugs and their use in the pharmaceutical field is subject to prior authorization as provided for in the United Nations Conventions of 1961 and 1971 and the national legislation on drugs (Decree of the President of the Republic 309/90 and subsequent amendments or single text of drugs). The inflorescences of cannabis plants with high THC content (> 0.2%) must be transformed into active substances of vegetable origin in accordance with the European directives in the field of medicinal products. In addition to the prior authorization to the cultivation, the law provides that the sale can be made only to pharmaceutical workshops authorised for processing into medicinal products and active substances. The delta - 9 - THC synthesis or dronabinol, active substance of the medicinal product Marinol, registered in the USA with indications in cases of loss of appetite and weight in patients with AIDS, is not classified by the INCB between narcotic substances (yellow list) but between the psychotropic substances (green list); nabilone, active substance of the medicinal product Cesamet, registered in the USA with indications as an antiemetic in course of chemotherapy, is under control in Italy and in some other countries. Any preparations with a basis of dronabinol require a prescription not repeatable. Up to now, for the realization of the preparations with vegetable products based on cannabis were imported into Italy only the products marketed by the Office of Medicinal Cannabis (Dutch agency for cannabis) of the Dutch Ministry of Health, Welfare and Sport, in accordance with the procedure for the scheduled import from DM 11/2/97. In 2016, our country has launched a national production of cannabis for medical use at the Military Pharmaceutical Chemical Works of Florence (SCFM), thanks to the collaboration between the Ministry of Health and the Ministry of Defense, in such a way as to ensure that the access to such therapies to appropriate costs and safely. This is the Cannabis product FM-2 (containing THC 5% - 8% and CBD 7.5% - 12%), before the active substance based on cannabis produced in accordance with the European directives in the field of medicinal products (EU - GMP) on production process deposited and controlled in a pharmaceutical workshop authorized by the AIFA and the distribution of which is authorized by the State body for cannabis at the Ministry of Health. The prescription of cannabis for medical use in Italy concerns (DM 9/11/2015) use in chronic pain and that associated with multiple sclerosis and spinal cord injury; in the nausea and vomiting caused by cancer chemotherapy, radiotherapy, therapy for HIV; as stimulating appetite in cachexia, Anorexia, loss of appetite in cancer patients or suffering from AIDS and anorexia nervosa; the hypotensive effect in glaucoma; the reduction of involuntary movements of the body and facial tissues in of Gilles de la Tourette Syndrome. The requirements are carried out when the conventional therapies or standard are ineffective. Information is available for doctors and pharmacists and instructions for the preparation of the decoction. In order to deepen see: Law 08 April 1998 , n. 94. Conversion to law, with amendments, of the decree-law of 17 February 1998, n. 23 laying down urgent provisions in the field of clinical trials in the field of oncology and other measures in the area of health. Order of 18 July 2006. Importation of medicines based on delta-9-tetrahydrocannabinol and trans-delta-9-tetrahydrocannabinol The Ministerial Decree of 18 April 2007. Updating and completion of the tables containing the indication of narcotic and psychotropic substances and related compositions medicinal products referred to in the decree of the President of the Republic 9 October 1990, n. 309, and subsequent modifications and integrations, bearing the consolidated text of the laws on discipline of narcotic drugs and psychotropic substances and of prevention, care and rehabilitation of the related member of drug addiction The Ministerial Decree of 23 January 2013. Update the tables containing the indication of narcotic and psychotropic substances, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent modifications and integrations. Insertion in Table II, Section B, of medicinal products of plant origin based on Cannabis (substances and preparations plants including extracts and tinctures) The plants of the genus cannabis are known for millennia and used in the past especially for the characteristics of resistance of the fiber for the production of fabrics and ropes. The genus cannabis spp. Comprises Species, varieties and subspecies indistinguishable between them as morphologically similar. All plants of the genus cannabis contain in various concentrations between 400 and 750 different substances, of these about 40 are cannabinoids including the tetrahydrocannabinol or THC and cannabidiol or CBD, active substances present in the medicinal products authorised in Italy and abroad (see American Herbal Pharmacopoeia). The inflorescences of cannabis are tabellate as drugs and their use in the pharmaceutical field is subject to prior authorization as provided for in the United Nations Conventions of 1961 and 1971 and the national legislation on drugs (Decree of the President of the Republic 309/90 and subsequent amendments or single text of drugs). The inflorescences of cannabis plants with high THC content (> 0.2%) must be transformed into active substances of vegetable origin in accordance with the European directives in the field of medicinal products. In addition to the prior authorization to the cultivation, the law provides that the sale can be made only to pharmaceutical workshops authorised for processing into medicinal products and active substances.